Epigenomics on the cusp of billion-dollar cancer screening opportunity
This article was originally published in Clinica
Executive Summary
Epigenomics is on a mission to build a world-leading molecular diagnostics company based on detecting DNA methylation in colorectal cancer patients. Joseph Harvey met with the German firm’s CEO, Geert Nygaard, to find out how it intends to achieve this goal and fend off competitors